Patients' Clinical Data at Diagnosis
| Patient No. . | Sex/Age . | HB . | WBC (×109/L) . | Platelet (×1012/L) . | APL Cell % in BM . | t(15; 17)/PML-RARα . | Previous Treatment Protocol . | |
|---|---|---|---|---|---|---|---|---|
| . | . | (g/L) . | . | . | . | . | CR-Induction . | Consolidation . |
| 1 | F/40 | 107.0 | 0.9 | 8.4 | 39.5 | +/ND | ATRA (40 mg × 30 d) | HA + DA |
| 2 | M/34 | 138.0 | 3.3 | 8.6 | 96.0 | +/L(+) | ATRA (40 mg × 22 d) | HA + DA + AA |
| 3 | M/41 | 84.0 | 0.8 | 52.0 | 19.5 | +/L(+) | ATRA (30 mg × 51 d) | HA + AA |
| 4 | M/43 | 76.0 | 3.4 | 56.9 | 32.0 | +/L(+) | ATRA (40 mg × 30 d) | HA + AA |
| 5 | M/34 | 126.0 | 1.5 | 7.7 | 70.0 | +/L(+) | ATRA (60 mg × 30 d) | AA |
| 6 | F/15 | 108.0 | 51.0 | 4.0 | 95.0 | +/L(+) | ATRA (30 mg × 30 d) | DA |
| 7 | M/53 | 75.0 | 4.0 | 5.0 | 85.0 | −/L(−)S(−) | ATRA (80 mg × 70 d) | HA + ATRA |
| 8 | F/15 | 75.0 | 3.8 | 76.0 | 72.0 | ND/L(+) | ATRA (15 mg × 30 d) | DA + ATRA |
| 9 | M/32 | 112.0 | 9.8 | 4.8 | 59.0 | ND | ATRA (60 mg × 47 d) | DA |
| 10 | M/14 | 127.0 | 3.1 | 23.6 | 90.0 | ND | ATRA (30 mg × 30 d) | HA |
| 11 | F/27 | 64.0 | 15.2 | 48.0 | 81.5 | +/S(+) | ATRA (80 mg × 30 d) | HA |
| ATRA (60 mg × 30 d)* | HA + AA + DA | |||||||
| 12 | M/42 | 115.0 | 4.0 | 13.6 | 12.5 | ND/L(+) | BHAC-DMP | MTX + Ara-c |
| BHAC-DMP* | MTX + Ara-c | |||||||
| ATRA (70 mg × 24 d)† | BHAC-DMP | |||||||
| 13 | F/53 | 122.0 | 4.6 | 10.8 | 44.0 | +/L(+) | ATRA (80 mg × 48 d) | DA + HA |
| ATRA (40 mg × 68 d)* | DA | |||||||
| 14 | M/49 | 65.0 | 0.6 | 4.0 | 71.0 | ND | BHAC-DMP | MTX + Ara-c |
| BHAC-DMP* | MTX + Ara-c | |||||||
| ATRA (70 mg × 24 d)† | BHAC-DMP | |||||||
| 15 | M/45 | 105.0 | 67.5 | 4.2 | 72.0 | +/L(+) | ATRA (30 mg × 50 d) | DA + HA |
| Patient No. . | Sex/Age . | HB . | WBC (×109/L) . | Platelet (×1012/L) . | APL Cell % in BM . | t(15; 17)/PML-RARα . | Previous Treatment Protocol . | |
|---|---|---|---|---|---|---|---|---|
| . | . | (g/L) . | . | . | . | . | CR-Induction . | Consolidation . |
| 1 | F/40 | 107.0 | 0.9 | 8.4 | 39.5 | +/ND | ATRA (40 mg × 30 d) | HA + DA |
| 2 | M/34 | 138.0 | 3.3 | 8.6 | 96.0 | +/L(+) | ATRA (40 mg × 22 d) | HA + DA + AA |
| 3 | M/41 | 84.0 | 0.8 | 52.0 | 19.5 | +/L(+) | ATRA (30 mg × 51 d) | HA + AA |
| 4 | M/43 | 76.0 | 3.4 | 56.9 | 32.0 | +/L(+) | ATRA (40 mg × 30 d) | HA + AA |
| 5 | M/34 | 126.0 | 1.5 | 7.7 | 70.0 | +/L(+) | ATRA (60 mg × 30 d) | AA |
| 6 | F/15 | 108.0 | 51.0 | 4.0 | 95.0 | +/L(+) | ATRA (30 mg × 30 d) | DA |
| 7 | M/53 | 75.0 | 4.0 | 5.0 | 85.0 | −/L(−)S(−) | ATRA (80 mg × 70 d) | HA + ATRA |
| 8 | F/15 | 75.0 | 3.8 | 76.0 | 72.0 | ND/L(+) | ATRA (15 mg × 30 d) | DA + ATRA |
| 9 | M/32 | 112.0 | 9.8 | 4.8 | 59.0 | ND | ATRA (60 mg × 47 d) | DA |
| 10 | M/14 | 127.0 | 3.1 | 23.6 | 90.0 | ND | ATRA (30 mg × 30 d) | HA |
| 11 | F/27 | 64.0 | 15.2 | 48.0 | 81.5 | +/S(+) | ATRA (80 mg × 30 d) | HA |
| ATRA (60 mg × 30 d)* | HA + AA + DA | |||||||
| 12 | M/42 | 115.0 | 4.0 | 13.6 | 12.5 | ND/L(+) | BHAC-DMP | MTX + Ara-c |
| BHAC-DMP* | MTX + Ara-c | |||||||
| ATRA (70 mg × 24 d)† | BHAC-DMP | |||||||
| 13 | F/53 | 122.0 | 4.6 | 10.8 | 44.0 | +/L(+) | ATRA (80 mg × 48 d) | DA + HA |
| ATRA (40 mg × 68 d)* | DA | |||||||
| 14 | M/49 | 65.0 | 0.6 | 4.0 | 71.0 | ND | BHAC-DMP | MTX + Ara-c |
| BHAC-DMP* | MTX + Ara-c | |||||||
| ATRA (70 mg × 24 d)† | BHAC-DMP | |||||||
| 15 | M/45 | 105.0 | 67.5 | 4.2 | 72.0 | +/L(+) | ATRA (30 mg × 50 d) | DA + HA |
Patients No. 11 and 13 were diagnosed at second relapse; patients No. 12 and 15 were diagnosed at third relapse; all other cases were at first relapse. For PML-RARα, L and S denote the long and short type isoforms of the fusion mRNA, respectively.12
Abbreviations: ND, not done; DA, Daunorubicin + Ara-C; HA, Harringtonin + Ara-C; AA, Aclamycin + Ara-C; BHAC-DMP, Benenoyl-Ara-C + daunomycin + 6-MP + Prednisone.
Protocol used for the second CR.
Protocol used for the third CR.